On May 13th, 2026, European Chemicals Agency (ECHA) opened public consultations on two review report applications for the continued authorized use of 4-Nonylphenol, branched and linear, ethoxylated under the EU REACH Authorisation framework. The consultations are open until July 8, 2026. The applications were submitted by Roche Diagnostics GmbH and concern the use of nonylphenol ethoxylates in the formulation, filling, and application of an in vitro diagnostic (IVD) assay identified as HIV combi PT. The consultations form part of the REACH authorisation review process, during which stakeholders may submit comments and relevant information for evaluation by ECHA’s scientific committees. Under the REACH Regulation, substances listed on the Authorisation List (Annex XIV) require authorization for continued use after sunset dates due to concerns regarding human health or environmental hazards. The consultation process supports assessment of whether the continued use remains justified and whether suitable alternatives are available. Comments submitted during the eight-week consultation period will support ECHA’s Committee for Risk Assessment (RAC) and Committee for Socio-economic Analysis (SEAC) in preparing opinions on the review applications.
Consumer News Region